INTRODUCTION
Thalassemias are the most common single gene disorder worldwide. 1 The incidence of thalassemia is very high, It is estimated that there are 35 million carrier of Thalassemia i.e. 1 in 25. Around 10 -15,000 babies with haemoglobinopathies are born in India every year. Blood transfusions therapy on continuing bases represent the primary treatment for β Thalassemia. Repeated blood transfusion leads to massive tissue deposition of iron &subsequently on long term basis causes multi organ dysfunction as a complication of it. 2 Mechanism of ocular manifestation in thalassemia is multifactorial. Thalassemia patients are taking regular blood transfusion therapy which causes iron overload. 
METHODS
This study was conducted in the thalassemia clinic, department of pediatrics, civil hospital, Ahmedabad for duration of 1 month. This study was cross sectional study of forty five children, diagnosed as β thalassemia major patients were visited thalassemia clinic for transfusion therapy in the month of October. The study was aimed at finding ocular manifestations in thalassemia patients with special reference to age, duration of disease, serum ferritin & to study the ocular manifestations in relation to dose and duration of deferasirox.
All children enrolled have been receiving treatment in the form of packed red cell transfusion at a dose of 10 ml/kg body weight transfusion in order to maintain their hemoglobin concentration between 9-11 gm/dl. Iron chelating agents were started if the serum Ferritin level was above 1000 µg/dl. An informed consent for participation was obtained from parents or legal guardians. Patients with any congenital ocular abnormalities were excluded. 
RESULTS
In our study ocular involvement was seen in 35.5% of patients of thalassemia, out of which 26% were having decreased visual acuity 26%, disc hyperemia 4.5%, tortuous retinal blood vessels 4.5%, retinal pigment mottling 2.5%, heterochromia 2.5%. Out of all patients, ocular manifestations present in 7 out of 15 males patients & 9 out of 14 patients with P value of 0.84, which was statistically not significant. Incidence of ocular involvement is seen in patients with S. ferritin levels >5000, which is 60%,while in group with S Ferritin level 3000-4999 it was 43.75% & 33.3 % in <3000. Ocular involvement was seen in 9 out of 12 in patients who have received chelation therapy for less than 5 years while in 7 out of 11 patients who received for more than 5 years with P value of 0.9, which is statistically not significant. So prolonged iron chelation therapy is not having direct causative effects on ocular involvement. Desferrioxamine and deferriprone, which are used to avoid systemic complications of siderosis cause chelation of metals such as iron, copper, zinc, cobalt and nickel in the retina. These metals are essential for normal retinal function. 3, 4 The aim of the study was to know the ocular manifestations in multiple transfused beta-thalassemia major patients and assess the ocular side-effects of ironchelating agents.
There are very few studies which consider the ocular side effects of thalassemia. Frequency of ocular involvement in our study was 35.5%, Gartagantis et al. 5 reported figures of 41.3%, Gaba A et al. 6 reported ocular involvement in 71.4% while Taneja et al. 7 reported figures of 58% of subjects in their respective studies. Visual acuity was affected in 26% patients while in Gaba et al. 6 study, the figure was and Taneja et al. 7 study, this figure was 67%.
In our study, increased serum ferritin is associated with increased ocular anomalies which are consistent with other studies. Duration of deferasirox has no direct relation with thalassemia. We found a larger number of thalassemic children to have ocular abnormalities despite only moderate doses of deferasirox and in the presences of high serum ferritin levels, which implicate a role of iron in ocular pathology in thalassemia. We recommend a larger study to evaluate the role of iron in ocular abnormalities in these patients. The reversibility of ocular changes should also be studied by changing the chelating agent or altering its dose.
A longer follow-up period is required to analyze and comment on how ocular changes may evolve. A limitation of the present study is that it cannot conclusively establish whether ocular changes are a result of the disease per se or due to iron-chelating agents. This requires stoppage of chelation therapy. It may be kept in mind though that iron overload and iron-chelating agents both may be mutually confounding factors in the causation of ocular changes of thalassemia. Also, patients enrolled in our study were already following a fixed thalassemia treatment regimen from elsewhere. In order to study the ocular manifestations of thalassemia in these patients and the ocular side-effects of iron-chelating agents, it was imperative that the treatment regimens being followed at presentation be continued.
A limitation of the present study is that it cannot conclusively establish whether ocular changes are a result of the disease or due to iron-chelating agents. This requires stoppage of chelation therapy which was not possible. It may be kept in mind though that iron overload and iron chelating agents both may be mutually confounding factors in the causation of ocular changes of Thalassemia.
CONCLUSION
Ocular changes of beta thalassemia are attributed to the course and severity of the disease. Serum ferritin is an important proxy indicator for ocular manifestations in thalassemia. Reduction in serum ferritin levels by ironchelating agents is useful for preventing adverse effects associated with iron overload and regular annual ocular evaluation is important to look for side-effects of such agents can aid in preventing or delaying ocular complications.
